EUVIMEDOpdag EUVIMED
Crossref

IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation

Chunsheng Tsao, Yongchen Ma, Feng Wang, Hang Yu iD, Yunlong Cai, Xudong Zhao, Taohua Yue, Long Rong iD

Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1516-1529

DOI: 10.1111/jgh.70331 ↗

At a glance

Journal article in Journal of Gastroenterology and Hepatology, published online on 2026-03-12. Written by Chunsheng Tsao and 7 co-authors. Institution: Department of Endoscopy Center, Peking University First Hospital, Peking, China. Major MEDLINE topics: Oxaliplatin, Stomach Neoplasms, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt. 37 references. Funded by: Beijing Municipal Natural Science Foundation, Foundation for Innovative Research Groups of the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Gastric cancer (GC) has poor prognosis and high chemoresistance. This study investigates IKZF3's role in GC progression, oxaliplatin resistance, and underlying mechanisms. IKZF3 expression in GC tissues/cells was assessed using TCGA, qPCR, Western blot, and immunohistochemistry. Prognostic significance was evaluated via Kaplan–Meier analysis. Lentiviral knockdown/overexpression of IKZF3 in HGC27 and AGS cells examined its effects on proliferation, invasion, migration, EMT,tumor stemness and oxaliplatin sensitivity in vitro and in vivo. Additionally, assess whether Iberdomide (an IKZF3 inhibitor) enhances chemosensitivity to oxaliplatin in GC cells in vivo. RNA sequencing (RNA‐seq) identified potential mechanisms. PI3K/AKT/mTOR pathway involvement was tested using PI3K inhibitor LY294002 in rescue experiments. IKZF3 was overexpressed in GC (TCGA/tissue microarrays) and correlated with poor prognosis. Knockdown suppressed proliferation, invasion, migration, EMT, tumor stemness and oxaliplatin resistance in HGC27 cells, while overexpression enhanced these in AGS/HGC27 cells. In vivo, IKZF3 knockdown or inhibitor Iberdomide reduced oxaliplatin resistance. RNA‐seq indicates that IKZF3 knockdown suppressed PI3K/AKT/mTOR pathway activity in HGC27 cells, while overexpression activated it in AGS cells. LY294002 reversed all oncogenic phenotypes and pathway changes induced by IKZF3 modulation. IKZF3 drives GC progression and oxaliplatin resistance by activating PI3K/AKT/mTOR signaling. It is a potential prognostic biomarker and therapeutic target, supporting further development of LY294002 and Iberdomide for GC treatment.

Subjects

MeSH terms (MEDLINE)

OxaliplatinStomach NeoplasmsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktDrug Resistance, NeoplasmPhosphatidylinositol 3-KinasesSignal TransductionIkaros Transcription FactorAntineoplastic AgentsHumansDisease ProgressionAnimalsCell ProliferationCell Line, TumorCell MovementNeoplasm InvasivenessMorpholinesChromones

Author keywords

IKZF3LY294002gastric canceriberdomideoxaliplatin

Substances

OxaliplatinTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesIkaros Transcription FactorMTOR protein, humanAntineoplastic Agents2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneMorpholinesChromones

Authors and institutions

  • Department of Endoscopy Center, Peking University First Hospital, Peking, China.

ORCID profiles: Hang Yu, Long Rong

Funding

  • Beijing Municipal Natural Science Foundation
  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Cite

APA

Tsao, C., Ma, Y., Wang, F., Yu, H., Cai, Y., Zhao, X., Yue, T., & Rong, L. (2026). IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. Journal of Gastroenterology and Hepatology, 41(5), 1516-1529. https://doi.org/10.1111/jgh.70331

Vancouver

Tsao C, Ma Y, Wang F, Yu H, Cai Y, Zhao X, et al. IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. Journal of Gastroenterology and Hepatology. 2026;41(5):1516-1529. doi:10.1111/jgh.70331

BibTeX
@article{Tsao2026,
  author = {Tsao, Chunsheng and Ma, Yongchen and Wang, Feng and Yu, Hang and Cai, Yunlong and Zhao, Xudong and Yue, Taohua and Rong, Long},
  title = {IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {5},
  pages = {1516--1529},
  doi = {10.1111/jgh.70331}
}
Start for free →